dr. andre goy on neoadjuvant leuprolide and abiraterone in high risk localized prostate cancer
Published 12 years ago • 609 plays • Length 1:35Download video MP4
Download video MP3
Similar videos
-
5:07
neoadjuvant abiraterone acetate plus leuprolide acetate in localised high-risk prostate cancer
-
2:04
a phase ii trial investigating neoadjuvant abiraterone and cabazitaxel in high-risk prostate cancer
-
5:04
neoadjuvant abiraterone acetate plus leuprolide acetate for localised high-risk prostate cancer
-
1:41
dr. mary-ellen taplin on neoadjuvant abiraterone acetate and leuprolide acetate
-
2:33
dr. leonard gomella on neoadjuvant hormonal therapy combined with abiraterone acetate
-
1:22
dr. charles ryan discusses neoadjuvant abiraterone acetate
-
1:49
dr. mary-ellen taplin on neoadjuvant adt plus hormonal therapy for prostate cancer
-
2:42
dr. goy highlights recent advances in oncology
-
0:46
dr. goy on the upcoming conference at john theurer cancer center
-
13:32
lecture on the role of neo adjuvant androgen deprivation before radical prostatectomy
-
1:48
dr. goy explains the concept of personalized medicine
-
1:22
dr. leonard gomella on the unique attributes of neoadjuvant zytiga
-
5:57
men with high-risk prostate cancer should not undergo neoadjuvant therapy prior to surgery
-
1:09
dr. dreicer on resistance to antiandrogen therapy in prostate cancer
-
8:28
metastatic prostate cancer: androgen receptor biology
-
12:24
anti-androgen trials
-
1:17
mk-0482-001: evaluating mk-0482 plus pembrolizumab in patients with advanced solid tumors
-
1:06
imaagen: phase 2 trial of abiraterone acetate for advanced prostate cancer
-
17:02
paul e. goss: extended adjuvant endocrine therapy in hormone-receptor bc